Moxifloxacin-Tetracycline-Lansoprazole Triple Therapy for First-Line Treatment of Helicobacter pylori Infection: A Prospective Study

Helicobacter

Volumn 16, Issue 1, 2011, Pages 52-54

  Tas, Adnan ^a   Akbal, Erdem ^a   Koçak, Erdem ^a   Köklü, Seyfettin ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

First line therapy; H. pylori; Lansoprazole; Moxifloxacine; Tetracycline

Indexed keywords

LANSOPRAZOLE; MOXIFLOXACIN; TETRACYCLINE; UREA C 13;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PREVALENCE; PRIORITY JOURNAL; PRURITUS; STOMACH ANTRUM; STOMACH BIOPSY; STRUCTURED QUESTIONNAIRE; TASTE DISORDER; UPPER GASTROINTESTINAL TRACT; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINOLINES; TETRACYCLINE; TREATMENT OUTCOME; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 78751564331     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00817.x     Document Type: Article

References (10)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
2. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994;35:742-5.
3. Us D, Hascelik G. Seroprevalence of Helicobacter pylori infection in an asymptomatic Turkish population. J Infect 1998;37:148-50.
4. Seyda T, Derya C, Fusun A, et al. The relationship of Helicobacter pylori positivity with age, sex, and ABO/Rhesus blood groups in patients with gastrointestinal complaints in Turkey. Helicobacter 2007;12:244-50.
5. Malfertheine P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
6. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of H. pylori with triple therapy. Gastroenterology 1992;102:493-6.
7. Cutler AF, Schubert TT. Patient factors affecting H. pylori eradication with triple therapy. Am J Gastroenterol 1993;88:505-9.
8. Yalin Kilic ZM, Köksal SA, Çakal B, et al. Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Dig Dis Sci 2008;53:3133-7.
9. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005;56:965-7.
10. Kearney DJ. Retreatment of H. pylori infection after initial treatment failure. Am J Gastroenterol 2001;96:1335-9.